Granisetron News and Research

RSS
Granisetron is the active ingredient in a drug used to treat nausea and vomiting caused by cancer treatment. Granisetron is a type of serotonin receptor antagonist and a type of antiemetic.
A.P. Pharma targets resubmission of APF530 NDA in 2012

A.P. Pharma targets resubmission of APF530 NDA in 2012

Nausea and vomiting are most feared of all chemotherapy-related side effects

Nausea and vomiting are most feared of all chemotherapy-related side effects

A.P. Pharma fourth quarter revenue decreases to $1.6 million

A.P. Pharma fourth quarter revenue decreases to $1.6 million

BDSI's BEMA drug delivery technology receives Canada patent

BDSI's BEMA drug delivery technology receives Canada patent

BDSI prices $15 million private placement

BDSI prices $15 million private placement

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

Solasia, ZIOPHARM enter license and collaboration agreement for darinaparsin product

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

PediatRx announces first-ever revenues and successful launch of GRANISOL

PediatRx announces first-ever revenues and successful launch of GRANISOL

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

BDSI initiates dosing in BEMA Buprenorphine Phase 3 clinical program for chronic pain

A.P. Pharma third quarter net loss increases to $1.7 million

A.P. Pharma third quarter net loss increases to $1.7 million

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BDSI to initiate BEMA Buprenorphine Phase 3 program following positive End-of-Phase 2 meeting with FDA

BREAKYL drug receives European approval

BREAKYL drug receives European approval

Lack of data on best way to treat nausea and vomiting in children undergoing chemotherapy

Lack of data on best way to treat nausea and vomiting in children undergoing chemotherapy

BDSI announces positive meeting with FDA, Meda on REMS program for ONSOLIS

BDSI announces positive meeting with FDA, Meda on REMS program for ONSOLIS

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

BDSI's Phase 2 study results of BEMA Buprenorphine selected for presentation at Pain Week 2010

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

A.P. Pharma second quarter 2010 net loss decreases to $0.09 per share

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Taro's granisetron tablets receive FDA approval

Taro's granisetron tablets receive FDA approval

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea

BDSI partners with Kunwha to develop and commercialize BEMA Fentanyl in Republic of Korea